Ido(Paz-Priel)Paz PrielMD

PubMed

• 1 citations
  Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex concentrate and em...
  Raquel Valls, Jonathan Wagg, Ido Paz-Priel, Gabriel Man, Laura Artigas, Georges Jaccard, Mireia Coma, Christophe Schmitt> ;Scientific Reports. 2023 Jun 21
• Mitigating Drug-Target-Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 Inhibitors.
  Jun-Ichi Nishimura, Antoine Soubret, Noriko Arase, Simon Buatois, Masaki Hotta, Jean-Eric Charoin, Yoshikazu Ito, Sasha Sreckovic, Hiroyuki Takamori, Christoph Bucher,...> ;Clinical Pharmacology and Therapeutics. 2023 Apr 1
• 12 citations
  Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies.
  Rebecca Kruse-Jarres, Flora Peyvandi, Johannes Oldenburg, Tiffany Chang, Sammy Chebon, Michelle Y Doral, Stacy E Croteau, Thierry Lambert, Christine L Kempton, Steven ...> ;Blood Advances. 2022 Dec 27
• 8 citations
  Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study.
  Anna Kiialainen, Markus Niggli, Christine L Kempton, Giancarlo Castaman, Tiffany Chang, Ido Paz-Priel, Joanne I Adamkewicz, Gallia G Levy> ;Haemophilia. 2022 Nov 1
• 4 citations
  Crovalimab for treatment of patients with paroxysmal nocturnal haemoglobinuria and complement C5 polymorphism: Subanalysis of the phase 1/2 COMPOSER study.
  Jun-Ichi Nishimura, Kensuke Usuki, Julia Ramos, Satoshi Ichikawa, Muriel Buri, Anna Kiialainen, Alexandre Sostelly, Régis Peffault de Latour, Ido Paz-Priel, Alexander ...> ;British Journal of Haematology. 2022 Aug 1
• 7 citations
  Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies.
  Aric Parnes, Johnny Mahlangu, Steven W. Pipe, Ido Paz-Priel, Michaela Lehle, Peter Trask, Víctor Jiménez-Yuste> ;Haemophilia. 2021 Oct 8
• 27 citations
  Low immunogenicity of emicizumab in persons with haemophilia A.
  Christophe Schmitt, Thomas Emrich, Sammy Chebon, Elena Fernandez, Claire Petry, Koichiro Yoneyama, Anna Kiialainen, Monet Howard, Markus Niggli, Ido Paz-Priel, Tiffany...> ;Haemophilia. 2021 Sep 4
• 16 citations
  The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN ...
  Mark W. Skinner, Claude Negrier, Ido Paz-Priel, Sammy Chebon, Víctor Jiménez-Yuste, Michael U. Callaghan, Michaela Lehle, Markus Niggli, Johnny Mahlangu, Amy D. Shapir...> ;Haemophilia. 2021 Jun 25
• 9 citations
  Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizuma...
  Christine L. Kempton, Peter Trask, Aric Parnes, Markus Niggli, Avrita Campinha-Bacote, Michael U. Callaghan, Niamh M O'Connell, Ido Paz-Priel, Johnny Mahlangu> ;Haemophilia. 2021 Jan 28
• 115 citations
  Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies
  Michael U. Callaghan, Claude Negrier, Ido Paz-Priel, Tiffany Chang, Sammy Chebon, Michaela Lehle, Johnny Mahlangu, Guy Young, Rebecca Kruse-Jarres, Maria Elisa Mancuso...> ;Blood. 2020 Dec 10
• 9 citations
  Determining meaningful health‐related quality‐of‐life improvement in persons with haemophilia A using the Haemophilia Quality of Life Questionnaire for Adults (Haem‐A‐...
  Sylvia von Mackensen, Olivier Catalani, Elina Asikanius, Ido Paz-Priel, Michaela Lehle, Peter Trask> ;Haemophilia. 2020 Oct 21
• Reply: RE: Reyes A, Révil C, Niggli M, et al. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: netwo...
  Adriana Reyes, Cedric Revil, Markus Niggli, Sammy Chebon, Simone Schlagmüller, J.-P. Flacke, Max Zortel, Ido Paz-Priel, Elina Asikanius, Roger J. Hampton, Anadi Mahaja...> ;Current Medical Research and Opinion. 2020 Apr 7
• 5 citations
  Effects and interferences of emicizumab, a humanized bispecific antibody mimicking activated factor VIII cofactor function, on lupus anticoagulant assays
  Joanne I. Adamkewicz, Anna Kiialainen, Ido Paz-Priel> ;International Journal of Laboratory Hematology. 2020 Apr 1
• 21 citations
  Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the...
  Adriana Reyes, Cedric Revil, Markus Niggli, Sammy Chebon, Simone Schlagmüller, J.-P. Flacke, Max Zortel, Ido Paz-Priel, Elina Asikanius, Roger J. Hampton, Anadi Mahaja...> ;Current Medical Research and Opinion. 2019 Aug 13
• 83 citations
  Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays
  Joanne I. Adamkewicz, David Chen, Ido Paz-Priel> ;Thrombosis and Haemostasis. 2019 May 7
• 23 citations
  Improved Behavior and Neuropsychological Function in Children With ROHHAD After High-Dose Cyclophosphamide.
  Lisa A. Jacobson, Shruti Rane, Lisa J. McReynolds, Diana Steppan, Allen R. Chen, Ido Paz-Priel> ;Pediatrics. 2016 Jul 1
• 26 citations
  C/EBPβ regulates sensitivity to bortezomib in prostate cancer cells by inducing REDD1 and autophagosome–lysosome fusion
  David J. Barakat, Janet Mendonca, Theresa Barberi, Jing Zhang, Sushant Kachhap, Ido Paz-Priel, Alan D. Friedman> ;Cancer Letters. 2016 May 28
• 29 citations
  CCAAT/Enhancer binding protein β controls androgen-deprivation-induced senescence in prostate cancer cells
  David J. Barakat, Jing Zhang, Theresa Barberi, Samuel R. Denmeade, Alan D. Friedman, Ido Paz-Priel> ;Oncogene. 2015 Nov 26
• 13 citations
  Loss of IKKβ but Not NF-κB p65 Skews Differentiation towards Myeloid over Erythroid Commitment and Increases Myeloid Progenitor Self-Renewal and Functional Long-Term H...
  Jing Zhang, Li Li, Albert S. Baldwin, Alan D. Friedman, Ido Paz-Priel> ;Plos One. 2015 Jun 23
• 3 citations
  Patterns of failure after involved field radiation therapy for pediatric and young adult Hodgkin lymphoma
  Minh-Phuong Huynh-Le, Amanda J. Walker, Scott Duke Kominers, Ido Paz-Priel, Moody D. Wharam, Stephanie A. Terezakis> ;Pediatric Blood & Cancer. 2014 Jul 1
• 17 citations
  A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-κB signaling in chordoma biology.
  Matteo Trucco, Ola Awad, Breelyn A. Wilky, Seth D. Goldstein, Ruili Huang, Robert L. Walker, Preeti Shah, Varalakshmi Katuri, Naheed Gul, Yuelin J. Zhu, Edward F. McCa...> ;Plos One. 2013 Nov 6
• 17 citations
  C/EBPα, C/EBPα Oncoproteins, or C/EBPβ Preferentially Bind NF-κB p50 Compared with p65 Focusing Therapeutic Targeting on the C/EBP:p50 Interaction
  Julia E. Dooher, Ido Paz-Priel, Simone Houng, Albert S. Baldwin, Alan D. Friedman> ;Molecular Cancer Research. 2011 Aug 3
• 37 citations
  C/EBPα and C/EBPα oncoproteins regulate nfkb1 and displace histone deacetylases from NF-κB p50 homodimers to induce NF-κB target genes
  Ido Paz-Priel, Simone Houng, Julia E. Dooher, Alan D. Friedman> ;Blood. 2011 Apr 14
• 33 citations
  Cyclophosphamide for rapid-onset obesity, hypothalamic dysfunction, hypoventilation, and autonomic dysregulation syndrome.
  Ido Paz-Priel, David W. Cooke, Allen R. Chen> ;The Journal of Pediatrics. 2011 Feb 1
• 39 citations
  C/EBPα dysregulation in AML and ALL.
  Ido Paz-Priel, Alan D. Friedman> ;Critical Reviews in Oncogenesis. 2011 Jan 1
• Join now to see all

Abstracts/Posters

• Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience
  Ido Paz-Priel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

• Preference for Emicizumab over Prior Factor Treatments: Results from the HAVEN 3 and HAVEN 4 Studies 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018